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a b s t r a c t
APOBEC3 proteins are DNA cytosine deaminases that restrict the replication of human immunodeﬁciency
virus deﬁcient in the counterdefense protein Vif. Here, we address the capacity of APOBEC3F to restrict
via deaminase-dependent and -independent mechanisms by monitoring spreading infections in diverse
T cell lines. Our data indicate that only a deaminase-proﬁcient protein is capable of long-term restriction
of Vif-deﬁcient HIV in T cells, analogous to prior reports for APOBEC3G. This indicates that the principal
mechanism of APOBEC3F restriction is deaminase-dependent.
& 2013 Elsevier Inc. All rights reserved.
Introduction
APOBEC3 proteins restrict human immunodeﬁciency virus type
1 (HIV) in the absence of the viral accessory protein Vif [reviewed
in (Albin and Harris, 2010; Malim and Bieniasz, 2012; Refsland and
Harris, 2013)]. It is generally agreed that enzymatic function is an
important component of the restriction mechanism, which results
in viral hypermutation and decreased cDNA accumulation [e.g.
(Harris et al., 2003; Mangeat et al., 2003; Yu et al., 2004; Zhang
et al., 2003) and recently reviewed in (Albin and Harris, 2013)]. In
addition, many have proposed diverse deaminase-independent
mechanisms of restriction [e.g. (Bishop et al., 2006, 2008; Guo
et al., 2006; Holmes et al., 2007; Iwatani et al., 2007; Li et al., 2007;
Luo et al., 2007; Mbisa et al., 2007, 2010; Newman et al., 2005;
Shindo et al., 2003; Yang et al., 2007)]. It is possible, however, that
some of these deaminase-independent mechanisms may repre-
sent transient overexpression artifacts since stable expression of
deaminase-deﬁcient APOBEC3G (A3G) fails to inhibit viral replica-
tion (Browne et al., 2009; Miyagi et al., 2007; Schumacher et al.,
2008). Although APOBEC3F (A3F) was initially thought to have
more prominent deaminase-independent effects (Holmes et al.,
2007), stable expression of A3F zinc coordination mutants in HeLa
cells also fails to restrict Vif-deﬁcient HIV in a single cycle of
replication (Miyagi et al., 2010).
We describe herein a series of studies designed to extend to
A3F these prior analyses of APOBEC3 deaminase activity in HIV
restriction using a spreading infection model that might better
represent conditions of natural infection. Like our predecessors,
we ﬁnd using novel cell lines stably expressing A3G catalytic
mutants that such mutants are incapable of efﬁciently restricting
Vif-deﬁcient HIV. Similarly, we ﬁnd that A3F catalytic mutants
exert little to no restrictive activity under similar conditions of
stable T cell expression. We subsequently conﬁrm the efﬁcacy of
both endogenously expressed and stably transfected wildtype A3F
for the restriction of HIV using Vif mutants selectively susceptible
to A3F but not A3G. We therefore conclude that deaminase activity
is required for efﬁcient restriction of Vif-deﬁcient HIV by A3F.
Results
Stable T cell expression of A3F catalytic mutants fails to restrict
Vif-deﬁcient HIV
To determine whether deaminase-deﬁcient A3F is capable of
restricting HIV in T cells, we stably transfected a permissive T cell
line, SupT11, with wildtype A3F, A3G or catalytic mutant deriva-
tives and isolated clones by limiting dilution as described pre-
viously [e.g. (Albin et al., 2010a, 2010b; Hultquist et al., 2011)].
Expression levels of untagged A3F and A3G in all resultant lines
were comparable between wildtype and mutant sets (Fig. 1).
We speciﬁcally used mutants of the catalytic glutamates in A3F
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(E251Q) and A3G (E259Q) since these show little or no discernible
encapsidation defect despite loss of deaminase activity [e.g.
(Holmes et al., 2007; Schumacher et al., 2008) and Fig. 2, which
shows encapsidation in virions produced by 293T cotransfection
with A3F-V5 and Vif-deﬁcient HIV expression plasmids]. Although
Fig. 2 does not directly demonstrate equal encapsidation efﬁciency
of A3F and its catalytic mutants in SupT11 cells, it does demon-
strate equal inherent encapsidation potential of the proteins in
question, which may not be assumed for all catalytic mutants [e.g.
(Holmes, et al., 2007)]. One may thus infer that A3F E251Q is
unlikely to be inherently disadvantaged in its ability to encapsidate.
Infections of all of these lines were initiated in parallel at
multiplicities of infection (MOIs) of 0.01 and 0.05 with either
wildtype or Vif-deﬁcient HIVIIIB containing tandem stop codons at
positions 26 and 27 of vif (Albin et al., 2010a, 2010b; Haché et al.,
2008). We have previously shown that similar conditions result in
restriction of Vif-deﬁcient HIVIIIB by wildtype A3F for at least
3 months or until the acquisition of adaptive viral mutations
(Albin et al., 2010a). Consistent with these data, stable expression
of either wildtype A3F or A3G in SupT11 restricts the spread of Vif-
deﬁcient HIVIIIB for the duration of the experiment (Fig. 3B and F).
In contrast, Vif-deﬁcient viruses peak within approximately
2 weeks on cell lines expressing catalytic mutants of each APOBEC3
protein with perhaps a modest delay among A3F E251Q lines in
comparison with A3G E259Q (Fig. 3D and H). Thus, the catalytic
glutamate and most likely deaminase activity itself are required
for efﬁcient restriction of HIV by stably expressed A3F or A3G in T
cell lines.
Selectively susceptible vif alleles conﬁrm the restrictive efﬁcacy
of endogenous A3F.
Although A3F restricts Vif-deﬁcient HIV efﬁciently at the levels
of expression demonstrated in our stably transfected cell lines,
another recent report found that the levels of A3F in ex vivo
peripheral blood mononuclear cells derived from several donors
are inadequate for restriction (Mulder et al., 2010). To assess the
effects of A3F in primary cells, the authors of this study utilized a
W11R Vif mutant that is capable of neutralizing A3G but not A3F.
For our part, we had previously abandoned similar lines of inquiry
on ﬁnding that mutants of the putative A3F-interacting region,
14DRMR17 (D14A), but not of the putative A3G-interacting region,
40YRHHY44 (Y40A), faithfully reproduce their transient overex-
pression phenotypes in stably transfected T cells (Russell and
Pathak, 2007).
To determine whether the levels of A3F or A3G in naturally
nonpermissive cells are adequate to restrict, we carried out addi-
tional experiments characterizing the spreading infection pheno-
types of the Vif W11R mutant along with three mutants of the
relevant putative A3F- or A3G-interacting regions that we had
identiﬁed incidentally in unrelated long-term passage experiments:
R15G, H43N and H43N/E117K (Albin and Harris, unpublished data).
Mutation of each of these residues has been previously shown to
ablate Vif anti-A3F (residues 11 and 15) or anti-A3G (residue 43)
activity in transient overexpression systems (He et al., 2008; Mulder
et al., 2010; Nagao et al., 2010; Pery et al., 2009; Russell and Pathak,
2007; Simon et al., 2005; Tian et al., 2006; Yamashita et al., 2008;
Yamashita et al., 2010; Zhang et al., 2008).
Consistent with transient overexpression data, each of the
mutants predicted to be susceptible to A3F, W11R or R15G, were
restricted in SupT11-A3F lines and in naturally nonpermissive
CEM2n cells that express endogenous A3F at levels slightly lower
than those found in primary CD4þ T cells (Refsland et al., 2012)
(Fig. 4A and C). The same mutants were not restricted in a SupT11-
A3G line (Fig. 4B). In comparison, mutants H43N and H43N in
combination with E117K were capable of spreading efﬁciently in
the presence of both A3F and A3G and showed a modest delay
in CEM2n cells, somewhat more pronounced for H43N versus the
H43N/E117K mutant (Fig. 4). These results are consistent with
prior long-term passages of 40YRHHY44 mutants in nonpermissive
CEM cells, wherein the authors observed no reversion of the
mutated residues, implying lack of selective pressure and, by
extension, largely intact anti-A3G function (Russell et al., 2009).
Combined with the prior observation that mutation of the putative
A3F-interacting region 14DRMR17 can result in the neutralization of
Vif-resistant A3G D128K (Schröfelbauer et al., 2006), these data
suggest that the losses of function associated with each region
may represent something more complex than simple loss of direct
interaction with Vif.
Discussion
We have described here T cell lines stably expressing A3F
E251Q that, in contrast to similar lines expressing wildtype A3F,
fail to restrict Vif-deﬁcient HIV. These results mirror those pre-
viously observed with A3G (Browne et al., 2009; Miyagi et al.,
2007; Schumacher et al., 2008), and together, we propose that
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Fig. 1. APOBEC3 expression levels in the cell lines used in this study. (A) A3F levels
found in SupT11 cells stably transfected with untagged A3F (code letter B followed
by a number to indicate a distinct, clonal line), A3F E251Q (code letter D) or a vector
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Fig. 2. Encapsidation of A3F catalytic mutants E251Q and W277A. Plasmids
expressing A3F-V5 or either of two catalytic mutant derivatives were cotransfected
with Vif-deﬁcient HIVIIIB. Virus-containing supernatants and producer cells were
harvested approximately 2 days post-transfection, and expression and encapsida-
tion were analyzed by western blot.
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both A3F and A3G require catalytic activity for the efﬁcient
restriction of Vif-deﬁcient HIV. Although unlikely based on many
experiments in our laboratory and others over the past decade,
we cannot exclude the hypothetical possibility that the catalytic
glutamate residue of these proteins may have an unknown
function in restriction beyond its described role catalyzing DNA
cytosine deamination. It is also formally possible that the encapsi-
dation efﬁciency of A3F and its E251Q derivative may differ in T
cells. The results shown in Fig. 2 with particles produced on 293T
cells, however, suggest that there is no inherent difference in the
encapsidation potential of these proteins, as previously shown for
A3G and A3G E259Q (e.g. Schumacher et al., 2008).
It also remains possible that expression of A3F and A3G in vivo
might hypothetically reach levels at which any of the deaminase-
independent mechanisms of restriction previously described in
transient overexpression studies might be active. This could be
particularly relevant for A3F, which may have greater deaminase-
independent effects than A3G both in transient overexpression
experiments and in primary CD4þ T cells (Gillick et al., 2013;
Holmes et al., 2007). It is telling, however, that even under
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Fig. 3. Deaminase activity is required for restriction of Vif-deﬁcient HIV by both A3F and A3G. Representative spreading infection curves infected at MOI 0.05 from one of
three independent experiments demonstrating the inability of catalytic mutants of A3F or A3G to efﬁciently restrict Vif-deﬁcient HIV. (A and B) Wildtype or Vif-deﬁcient
HIVIIIB on four independent cell lines expressing wildtype A3F. (C and D) On four independent cell lines expressing A3F E251Q. (E and F) On four independent cell lines
expressing wildtype A3G. (G and H) On four independent cell lines expressing A3G E259Q. Cell lines in all panels are named as in Fig. 1. Variation in time to peak and in the
height of peaks reﬂects the fact that each cell line used is an independent subclone. Note also that the peak of infectious virion production is typically followed shortly
thereafter by a rapid drop in detected infectious virus. This reﬂects viral cytopathic effects in permissive cultures where HIV successfully spreads, which results in the death
of the permissive producer cell cultures shortly after peak infectious virion production. In the absence of surviving producer cells, no infectious virion production is detected.
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conditions of likely overexpression in SupT11 cells, A3F E251Q and
A3G E259Q are unable to restrict Vif-deﬁcient HIV (Fig. 3). In the
absence of data concerning the exact induction conditions under
which deaminase-independent restriction might occur, we must
for time being conclude that the predominant mechanism of
restriction by A3F and A3G is deaminase-dependent.
Recent papers have also called into question the ability of even
wildtype A3F to restrict Vif-deﬁcient HIV when stably or endo-
genously expressed (Miyagi et al., 2010; Mulder et al., 2010). To
conﬁrm the results seen in our analyses of wildtype versus
catalytic mutant stable expression in SupT11, we also used Vif
mutants selectively susceptible to either A3F or A3G (Mulder et al.,
2010; Russell and Pathak, 2007; Simon et al., 2005). As shown in
Fig. 4, both the W11R and the R15G mutants in or around the
14DRMR17 region thought to be important for A3F interaction fail
to spread both in SupT11 lines stably transfected with A3F and in
naturally nonpermissive CEM2n cells, which have been previously
shown to express endogenous A3F at levels even lower than those
in primary CD4þ cells (Refsland et al., 2012), implying the efﬁcacy
of A3F in restriction. It is likely that A3D also contributes to
restriction in CEM2n (and in the peripheral mononuclear blood
cells utilized in other studies) and thereby may lead to over-
estimates of the efﬁcacy of A3F (Hultquist et al., 2011; Refsland
et al., 2012). However, given the ability of multiple lines stably
transfected with A3F to restrict over many studies (Albin et al.,
2010a, 2010b; Haché et al., 2008; Han et al., 2008; Hultquist et al.,
2011) and the apparently weaker restrictive abilities of A3D
(Hultquist et al., 2011), we think this unlikely.
It has been previously proposed that the inability of peripheral
mononuclear blood cells to restrict HIV was a result of low A3F
expression levels in the samples used (Mulder et al., 2010). This is
possible, albeit at odds with the restriction of vif mutants W11R
and R15G by CEM2n cells in Fig. 4, but it is notable that a more
recent analysis of the relative restrictive capacities of A3D, A3F and
A3G failed to demonstrate long-term restriction by even A3G in
primary CD4þ T cells (Chaipan et al., 2013). Like Mulder et al.,
these authors observed robust restriction of a Vif mutant suscep-
tible to all APOBEC3 proteins but not of a Vif mutant susceptible to
one or two APOBEC3 proteins. Rather than signaling a hierarchy of
relative importance as implied by the modest differential delays
observed by Chaipan et al., it may therefore be more accurate to
say that restriction in primary cells reﬂects the cumulative effects
of multiple APOBEC3 proteins. Alternatively, there may be some-
thing fundamentally different about the mechanism of restriction
and/or the requirement for Vif in primary cells that accounts for
these results.
A curious observation made in the course of these studies is the
inability of A3G to robustly restrict T cell spread by Vif-proﬁcient
viruses with a mutation in the 40YRHHY44 region thought to be
important for binding to A3G (Russell and Pathak, 2007). Although
not widely noted, such results have been implied twice before
(Chaipan et al., 2013; Russell et al., 2009). Russell et al.'s manu-
script is particularly notable between the two of these because
it describes long-term passages of 40YRHHY44 mutant viruses in
naturally nonpermissive CEM cells. Despite ample opportunity
for the virus to revert these presumably deleterious mutations, the
40YRHHY44 mutations remained intact throughout passage
(Russell et al., 2009), implying a lack of selective pressure in this
spreading infection system despite what would be predicted based
on single-cycle replication experiments. Combined with the ability
of mutants in the putative A3F-binding 14DRMR17 region to reverse
the Vif-resistant phenotype of A3G D128K (Schröfelbauer et al.,
2006), it seems unlikely that 14DRMR17 and 40YRHHY44 are simply
regions Vif that directly interact with A3F or A3G, respectively.
Conclusions
In conclusion, we have shown that the restriction of HIV by A3F
requires intact deaminase activity. We have also conﬁrmed prior
reports demonstrating the importance of deaminase activity for
HIV restriction by A3G. These results suggest that the predominant
driving force for the maintenance of Vif function by HIV centers on
the deaminase-dependent restriction mechanisms previously
described. We further note that not all vif mutations thought to
yield selective susceptibility to one APOBEC3 protein or another
have notable spreading infection phenotypes. This may complicate
the attempt to use such mutants in parsing the in vivo contribu-
tions of various APOBEC3 proteins and further suggests that the
growing literature on loss of function vif mutations will need to be
carefully interpreted as regards deﬁning the regions of Vif that
directly interact with A3F and A3G [reviewed in (Albin and Harris,
2010; Smith et al., 2009)]. Insofar as one can trust the phenotypes
of these loss of function mutants, however, they appear to support
a model wherein A3F is at least as relevant as A3G to the overall
nonpermissive phenotype in nonpermissive T cell lines. Knowl-
edge of the in vivo relevance of distinct APOBEC3 proteins, by
contrast, is not as well deﬁned.
Materials and methods
Plasmid generation
Wildtype A3F and A3G are identical to GenBank NM_145298
and NM_021822, respectively, as previously described (Albin et al.,
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Fig. 4. Mutation of the putative A3F-interacting region of Vif but not the putative A3G-interacting region of Vif yields viruses selectively susceptible to the predicted
APOBEC3 protein. (A) Growth of wildtype, Vif-deﬁcient and the indicated Vif mutant derivatives of HIVIIIB in the presence of A3F. (cell line B8 in Fig. 1A). (B) Growth of
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2010a, 2010b; Haché et al., 2008). Variants A3F E251Q and A3G
E259Q were generated by QuikChange site-directed mutagenesis
(Stratagene) and conﬁrmed by DNA sequencing. V5-tagged deri-
vatives as shown in Fig. 2 were derived by similar methods as
previously described (Albin et al., 2010a, 2010b, 2013).
HIVIIIB and a derivative containing tandem stop codons at
positions 26 and 27 of vif are identical to GenBank EU541617 with
the exception of an A200C mutation that corrects an aberrant
upstream open reading frame that would otherwise inhibit viral
gene expression, as previously described (Albin et al., 2010a,
2010b, 2013; Haché et al., 2008, 2009). Vif mutants were gener-
ated by site-directed mutagenesis in a shuttle vector containing
the vif–vpr segment of HIVIIIB, which was subsequently subcloned
back into a full-length proviral background using the SwaI and SalI
sites, as previously described (Albin et al., 2010a).
Cell lines
CEM-GFP and SupT11-derived T cell lines were maintained in
RPMI media containing 10% fetal bovine serum, penicillin/strepto-
mycin and β-mercaptoethanol. 293T cells were cultured in DMEM
containing 10% fetal bovine serum and penicillin/streptomycin.
The generation of SupT11-derived cell lines expressing single
wildtype or variant APOBEC3 proteins has been described pre-
viously (Albin et al., 2010a, 2010b). SupT11 is a clonal derivative of
SupT1 isolated by limiting dilution and found to have undetectable
expression A3F and A3G and little if any expression of other
APOBEC3 proteins (Refsland et al., 2010). Brieﬂy, SupT11 cells were
electroporated with 20 mg linearized plasmid, plated at several
dilutions in 96-well plates and selected in G418-containing RPMI.
Single-cell clones were then expanded and analyzed by western
blot for expression of A3F or A3G, as indicated below and shown in
Fig. 1.
Encapsidation
A3F-V5 or catalytic mutant derivatives E251Q or W277A were
cotransfected with Vif-deﬁcient HIVIIIB. Two days post-transfection,
transfected cells and virus-containing supernatants were harvested.
Viruses were pelleted through 20% sucrose cushions and lysed in a
5 sample buffer consisting of 62.5 mM Tris pH 6.8, 20% glycerol,
2% sodium dodecyl sulfate and 5% β-mercaptoethanol. A3F-V5 levels
expressed or encapsidated were then analyzed by western blot
methods similar to those described below for the analysis of
APOBEC3 expression levels in T cell lines, probing for V5 (Invitro-
gen), p24 (antibodies puriﬁed from hybridoma cell line 183-H12-5C
from the AIDS Research and Reference Reagent Program) or tubulin
(Covance).
Western blots
Expression of APOBEC3 proteins in SupT11-derived cell lines
was assessed by lysing individual lines in a buffer consisting of
25 mM HEPES pH 7.4, 150 mM NaCl, 1 mM MgCl2, 10% glycerol and
1% Triton X-100 with 50 μM MG132 and complete protease
inhibitor (Roche). Lysates were then mixed with the 5 sample
buffer described above to a ﬁnal concentration of 2 . This mix
was boiled for 10 min and loaded onto 10% sodium dodecyl sulfate
polyacrylamide gels for fractionation by electrophoresis prior to
transfer to polyvinylidene ﬂuoride membranes.
Membranes were blocked with 4% milk in 0.1% Tween diluted in
phosphate-buffered saline. These were then probed either with
rabbit anti-A3F (Dr. Michael Malim, #1474 via the AIDS Research
and Reference Reagent Program), rabbit anti-A3G (Dr. Jaisri Lingappa,
#10201 via the AIDS Research and Reference Reagent Program) or
mouse anti-tubulin (Covance) followed by horseradish peroxidase
(HRP) conjugated secondary antibodies as appropriate. HRP activity
was then detected by treatment with HyGLO chemiluminescent HRP
detection reagent (Denville) and exposure to ﬁlm. Between distinct
primary antibodies, membranes were stripped with a buffer contain-
ing 62.5 mM Tris pH 6.8, 2% sodium dodecyl sulfate and 100 mM β-
mercaptoethanol at 50 1C and washed in phosphate-buffered saline
with 0.1% Tween.
Spreading infections
Viruses were produced by transfecting 293T cells in 10 cm dishes
with 5–10 μg proviral plasmid DNA. Virus-containing supernatants
were then harvested, passed through 0.45 μm ﬁlters and frozen. An
aliquot of each virus preparation was thawed and titrated on CEM-
GFP cells in 96-well plates, and the volume corresponding to a given
percentage of cells infected was calculated to normalize starting
quantities.
Volumes of wildtype or Vif-deﬁcient HIVIIIB corresponding to
MOI 0.01 or 0.05 were used to initiate spreading infections on four
SupT11-derived cell lines each expressing A3F, A3F E251Q, A3G or
A3G E259Q as well as SupT11-derived lines stably transfected with
an empty vector control and naturally nonpermissive CEM2n cells.
Infections utilizing vif mutants as described in the main text were
initiated in similar fashion. Following infection of 50,000 target
cells with normalized virus quantities in a total volume of 1 mL in
24-well plates, viral spread was monitored periodically by using
150 μL of supernatant to infect 25,000 CEM-GFP cells in 96-well
plates in a total volume of 250 μL. Three days later, infected CEM-
GFP reporter cells were ﬁxed in 4% paraformaldehyde and ana-
lyzed by ﬂow cytometry using a FACSCalibur instrument (Becton–
Dickinson) with subsequent data analysis in FlowJo software (Tree
Star). Infected 24-well plate cultures were periodically split and
fed to prevent cell overgrowth.
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